BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte Reports Second Quarter 2026 Financial Results

MaxCyte (MXCT)MaxCyteEarnings

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share

Related news

MXCTMaxCyte2026-07-15 20:05 EST

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

CRBUCaribou2026-08-13 20:05 EST

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

MGTXMeiraGTx2026-08-13 12:00 EST

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SANASana Biotechnology2026-08-10 20:05 EST

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

OCGNOcugen2026-08-06 11:02 EST

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

View all latest news

MaxCyte

Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...

Recent company news

MXCTMaxCyte2026-08-19 12:05 EST

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MXCTMaxCyte2026-08-12 20:05 EST

MaxCyte Reports Second Quarter 2026 Financial Results

MXCTMaxCyte2026-07-21 12:05 EST

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MXCTMaxCyte2026-07-15 20:05 EST

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MXCTMaxCyte2026-06-23 13:00 EST

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

Stock data

Close
1.38 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States